Mark L. Bernstein

14.0k total citations · 1 hit paper
184 papers, 7.5k citations indexed

About

Mark L. Bernstein is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Mark L. Bernstein has authored 184 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 47 papers in Pulmonary and Respiratory Medicine and 40 papers in Neurology. Recurrent topics in Mark L. Bernstein's work include Neuroblastoma Research and Treatments (38 papers), Sarcoma Diagnosis and Treatment (32 papers) and Cancer therapeutics and mechanisms (26 papers). Mark L. Bernstein is often cited by papers focused on Neuroblastoma Research and Treatments (38 papers), Sarcoma Diagnosis and Treatment (32 papers) and Cancer therapeutics and mechanisms (26 papers). Mark L. Bernstein collaborates with scholars based in United States, Canada and Switzerland. Mark L. Bernstein's co-authors include Mark Krailo, Susan M. Blaney, Holcombe E. Grier, Michael B. Harris, Allen M. Goorin, Neyssa Marina, Mark C. Gebhardt, John Moreland, Richard L. Momparler and Meenakshi Devidas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Mark L. Bernstein

183 papers receiving 7.3k citations

Hit Papers

Osteosarcoma: The Additio... 2008 2026 2014 2020 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
    2008 520 citations Paul A. Meyers, Cindy L. Schwartz et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark L. Bernstein 2.7k 2.2k 1.8k 1.7k 1.1k 184 7.5k
Victor M. Santana 1.4k 0.5× 2.0k 0.9× 2.0k 1.1× 1.6k 0.9× 568 0.5× 148 5.4k
Teresa J. Vietti 4.6k 1.7× 1.4k 0.6× 2.2k 1.2× 1.3k 0.7× 1.9k 1.7× 149 8.0k
Allen M. Goorin 3.4k 1.2× 1.1k 0.5× 2.0k 1.1× 477 0.3× 986 0.9× 56 6.2k
A. Zoubek 4.7k 1.7× 1.6k 0.7× 1.6k 0.9× 670 0.4× 1.2k 1.1× 101 6.6k
CR Pinkerton 1.4k 0.5× 999 0.4× 1.5k 0.8× 1.3k 0.7× 713 0.6× 157 5.2k
Najat C. Daw 2.7k 1.0× 1.4k 0.6× 1.2k 0.7× 507 0.3× 724 0.6× 154 4.7k
Wayne L. Furman 1.1k 0.4× 1.7k 0.8× 1.9k 1.1× 1.6k 0.9× 944 0.8× 197 6.1k
Gianni Bisogno 5.2k 1.9× 1.3k 0.6× 2.4k 1.3× 1.3k 0.8× 2.6k 2.3× 336 8.2k
Serge Leyvraz 3.2k 1.2× 1.9k 0.9× 3.4k 1.9× 633 0.4× 1.2k 1.0× 214 8.5k
Graça M. Dores 1.9k 0.7× 1.6k 0.7× 2.9k 1.6× 446 0.3× 1.9k 1.7× 83 8.1k

Countries citing papers authored by Mark L. Bernstein

Since Specialization
Citations

This map shows the geographic impact of Mark L. Bernstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Bernstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Bernstein more than expected).

Fields of papers citing papers by Mark L. Bernstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark L. Bernstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Bernstein. The network helps show where Mark L. Bernstein may publish in the future.

Co-authorship network of co-authors of Mark L. Bernstein

This figure shows the co-authorship network connecting the top 25 collaborators of Mark L. Bernstein. A scholar is included among the top collaborators of Mark L. Bernstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark L. Bernstein. Mark L. Bernstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Collier, Anderson B., Mark Krailo, Ha Dang, et al.. (2021). Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 68(12). e29333–e29333. 13 indexed citations
2.
3.
Schwartz, Cindy L., Leonard H. Wexler, Mark Krailo, et al.. (2015). Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. Pediatric Blood & Cancer. 63(1). 54–61. 64 indexed citations
4.
Barkauskas, Donald A., Mark Krailo, Sajida Piperdi, et al.. (2014). HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatric Blood & Cancer. 61(9). 1558–1564. 17 indexed citations
5.
Hook, Jennifer, Gordana Jovic, Neyssa Marina, et al.. (2012). Lack of trial participation and lack of centralization for young adults with osteosarcoma: Experience from the European and American Osteosarcoma Study, EURAMOS-1. UCL Discovery (University College London). 1 indexed citations
6.
Meyers, Paul A., Holcombe E. Grier, Mark L. Bernstein, et al.. (2012). Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 30(20). 2545–2551. 184 indexed citations
7.
Granowetter, Linda, Richard B. Womer, Meenakshi Devidas, et al.. (2009). Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology. 27(15). 2536–2541. 235 indexed citations
8.
Meyers, Paul A., Cindy L. Schwartz, Mark Krailo, et al.. (2008). Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group. Journal of Clinical Oncology. 26(4). 633–638. 520 indexed citations breakdown →
9.
Lemaire, Maryse, Louise F. Momparler, Noël J.‐M. Raynal, Mark L. Bernstein, & Richard L. Momparler. (2008). Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine. Cancer Chemotherapy and Pharmacology. 63(3). 411–416. 42 indexed citations
10.
Mondick, John, Bhuvana Jayaraman, Patrick A. Thompson, et al.. (2008). Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemotherapy and Pharmacology. 63(2). 229–238. 63 indexed citations
11.
Yock, Torunn I., Mark Krailo, Christopher Fryer, et al.. (2006). Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091—A Report From the Children's Oncology Group. Journal of Clinical Oncology. 24(24). 3838–3843. 100 indexed citations
12.
Woods, William G., et al.. (2005). Health and Economic Benefits of Well-Designed Evaluations: Some Lessons From Evaluating Neuroblastoma Screening. JNCI Journal of the National Cancer Institute. 97(15). 1118–1124. 8 indexed citations
13.
Dalle, Jean‐Hugues, Albert Moghrabi, Pierre Rousseau, et al.. (2005). Second Induction in Pediatric Patients With Recurrent Acute Lymphoid Leukemia Using DFCI-ALL Protocols. Journal of Pediatric Hematology/Oncology. 27(2). 73–79. 3 indexed citations
14.
15.
Bernstein, Mark L., Thomas C. Abshire, Brad H. Pollock, et al.. (1997). Idarubicin and Cytosine Arabinoside Reinduction Therapy for Children with Multiple Recurrent or Refractory Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study. ˜The œAmerican journal of pediatric hematology/oncology. 19(1). 68–72. 16 indexed citations
16.
Woods, William G., Mendel Tuchman, Leslie L. Robison, et al.. (1996). A population-based study of the usefulness of screening for neuroblastoma. The Lancet. 348(9043). 1682–1687. 161 indexed citations
17.
Hachitanda, Yoichi, William G. Woods, Mendel Tuchman, et al.. (1995). Screening for neuroblastoma in north america. Preliminary results of a pathology review from the quebec project. Cancer. 76(11). 2363–2371. 23 indexed citations
18.
Kung, Faith, Charles B. Pratt, Roger A. Vega, et al.. (1993). Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study. Cancer. 71(5). 1898–1903. 87 indexed citations
19.
Woods, William G., Mendel Tuchman, Mark L. Bernstein, et al.. (1992). Screening for Neuroblastoma in North America. The Pediatric Infectious Disease Journal. 14(4). 312–319. 4 indexed citations
20.
Bernstein, Mark L.. (1983). The Application of Photography in Forensic Dentistry. Dental Clinics of North America. 27(1). 151–170. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victor M. Santana Breakdown of academic impact, for papers by Teresa J. Vietti Breakdown of academic impact, for papers by Allen M. Goorin Breakdown of academic impact, for papers by A. Zoubek Breakdown of academic impact, for papers by CR Pinkerton Breakdown of academic impact, for papers by Najat C. Daw Breakdown of academic impact, for papers by Wayne L. Furman Breakdown of academic impact, for papers by Gianni Bisogno Breakdown of academic impact, for papers by Serge Leyvraz Breakdown of academic impact, for papers by Graça M. Dores
Rankless by CCL
2026